Literature DB >> 15170040

Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation.

A De Soyza1, K Morris, A McDowell, C Doherty, L Archer, J Perry, J R W Govan, P A Corris, K Gould.   

Abstract

BACKGROUND: It has previously been reported that patients infected with Burkholderia cenocepacia (genomovar III) before lung transplantation have a poorer outcome than those with other B. cepacia complex infections.
METHODS: An extensive study was conducted to determine the prevalence and clonality of B. cepacia complex genomovars isolated from patients referred for transplant assessment between 1989 to the present and, where appropriate, whether strain type was related to transplant outcome.
RESULTS: Isolates from 29 patients were identified as B. cepacia complex organisms by molecular analysis. Thirteen patients (45%) were infected with the highly transmissible ET-12 strain of B. cenocepacia recA lineage III-A, while all remaining patients were infected with genetically unique B. cenocepacia, B. multivorans, and B. vietnamiensis strains. All previously reported deaths following transplantation were associated with ET-12 infection.
CONCLUSIONS: The ET-12 strain is the predominant cause of B. cenocepacia infections in patients with cystic fibrosis referred to our pulmonary transplant centre and is associated with poor transplant outcomes using standard treatment regimens.

Entities:  

Mesh:

Year:  2004        PMID: 15170040      PMCID: PMC1747049          DOI: 10.1136/thx.2003.010801

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

1.  Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis.

Authors:  A De Soyza; A McDowell; L Archer; J H Dark; S J Elborn; E Mahenthiralingam; K Gould; P A Corris
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

2.  Activity of disinfectants against Gram-negative bacilli isolated from patients undergoing lung transplantation for cystic fibrosis.

Authors:  John D Perry; Gavin Riley; Susan Johnston; John H Dark; F Kate Gould
Journal:  J Heart Lung Transplant       Date:  2002-11       Impact factor: 10.247

3.  Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis.

Authors:  E Mahenthiralingam; D A Simpson; D P Speert
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

4.  Burkholderia cepacia complex in cystic fibrosis and non-cystic fibrosis patients: identification of a cluster of epidemic lineages.

Authors:  A Agodi; M Barchitta; V Gianninò; A Collura; T Pensabene; M L Garlaschi; C Pasquarella; F Luzzaro; F Sinatra; E Mahenthiralingam; S Stefani
Journal:  J Hosp Infect       Date:  2002-03       Impact factor: 3.926

5.  Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation.

Authors:  C Chaparro; J Maurer; C Gutierrez; M Krajden; C Chan; T Winton; S Keshavjee; M Scavuzzo; E Tullis; M Hutcheon; S Kesten
Journal:  Am J Respir Crit Care Med       Date:  2001-01       Impact factor: 21.405

6.  Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type.

Authors:  R M Aris; J C Routh; J J LiPuma; D G Heath; P H Gilligan
Journal:  Am J Respir Crit Care Med       Date:  2001-12-01       Impact factor: 21.405

7.  DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III.

Authors:  E Mahenthiralingam; J Bischof; S K Byrne; C Radomski; J E Davies; Y Av-Gay; P Vandamme
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

8.  Six-year molecular analysis of Burkholderia cepacia complex isolates among cystic fibrosis patients at a referral center for lung transplantation.

Authors:  David G Heath; Kathy Hohneker; Charlene Carriker; Kelly Smith; Jonathan Routh; John J LiPuma; Robert M Aris; David Weber; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

9.  Burkholderia cenocepacia sp. nov.--a new twist to an old story.

Authors:  Peter Vandamme; Barry Holmes; Tom Coenye; Johan Goris; Eshwar Mahenthiralingam; John J LiPuma; John R W Govan
Journal:  Res Microbiol       Date:  2003-03       Impact factor: 3.992

Review 10.  Burkholderia cepacia complex infection in patients with cystic fibrosis.

Authors:  Eshwar Mahenthiralingam; Adam Baldwin; Peter Vandamme
Journal:  J Med Microbiol       Date:  2002-07       Impact factor: 2.472

View more
  9 in total

1.  Revised approach for identification of isolates within the Burkholderia cepacia complex and description of clinical isolates not assigned to any of the known genomovars.

Authors:  Jane F Turton; Nazia Arif; Daneeta Hennessy; Mary E Kaufmann; Tyrone L Pitt
Journal:  J Clin Microbiol       Date:  2007-07-11       Impact factor: 5.948

2.  Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy.

Authors:  S Campana; G Taccetti; N Ravenni; F Favari; L Cariani; A Sciacca; D Savoia; A Collura; E Fiscarelli; G De Intinis; M Busetti; A Cipolloni; A d'Aprile; E Provenzano; I Collebrusco; P Frontini; G Stassi; M Trancassini; D Tovagliari; A Lavitola; C J Doherty; T Coenye; J R W Govan; P Vandamme
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Identification of the flagellin glycosylation system in Burkholderia cenocepacia and the contribution of glycosylated flagellin to evasion of human innate immune responses.

Authors:  Anna Hanuszkiewicz; Paula Pittock; Fiachra Humphries; Hermann Moll; Amanda Roa Rosales; Antonio Molinaro; Paul N Moynagh; Gilles A Lajoie; Miguel A Valvano
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

5.  Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.

Authors:  Akshu Balwan; David P Nicolau; Minkey Wungwattana; Jonathan B Zuckerman; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2015-12-31       Impact factor: 5.191

6.  Developing an international Pseudomonas aeruginosa reference panel.

Authors:  Anthony De Soyza; Amanda J Hall; Eshwar Mahenthiralingam; Pavel Drevinek; Wieslaw Kaca; Zuzanna Drulis-Kawa; Stoyanka R Stoitsova; Veronika Toth; Tom Coenye; James E A Zlosnik; Jane L Burns; Isabel Sá-Correia; Daniel De Vos; Jean-Paul Pirnay; Timothy J Kidd; David Reid; Jim Manos; Jens Klockgether; Lutz Wiehlmann; Burkhard Tümmler; Siobhán McClean; Craig Winstanley
Journal:  Microbiologyopen       Date:  2013-11-11       Impact factor: 3.139

7.  Burkholderia cenocepacia ET12 strain activates TNFR1 signalling in cystic fibrosis airway epithelial cells.

Authors:  Umadevi S Sajjan; Marc B Hershenson; Janet F Forstner; John J LiPuma
Journal:  Cell Microbiol       Date:  2007-08-14       Impact factor: 3.715

8.  Burkholderia PglL enzymes are Serine preferring oligosaccharyltransferases which target conserved proteins across the Burkholderia genus.

Authors:  Andrew J Hayes; Jessica M Lewis; Mark R Davies; Nichollas E Scott
Journal:  Commun Biol       Date:  2021-09-07

9.  Biofilm-grown Burkholderia cepacia complex cells survive antibiotic treatment by avoiding production of reactive oxygen species.

Authors:  Heleen Van Acker; Andrea Sass; Silvia Bazzini; Karen De Roy; Claudia Udine; Thomas Messiaen; Giovanna Riccardi; Nico Boon; Hans J Nelis; Eshwar Mahenthiralingam; Tom Coenye
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.